SCHEDULE 13G/A: Nikko Asset Management Americas Discloses 5% Stake in 10x Genomics

Nikko Asset Management Americas, Inc., a subsidiary of Sumitomo Mitsui Trust Group, has disclosed a 5% beneficial ownership stake in 10x Genomics, Inc. Class A common stock as of March 31, 2025.

Summary

• Nikko Asset Management Americas, Inc. has filed an Amendment No. 1 to Schedule 13G, detailing its beneficial ownership in 10x Genomics, Inc.
• The filing indicates beneficial ownership of 5,362,656 shares of 10x Genomics, Inc. Class A common stock.
• This aggregate amount represents 5.0% of the issuer's Class A common stock.
• Nikko Asset Management Americas, Inc. holds shared voting power over 5,108,145 shares and shared dispositive power over 5,362,656 shares.
• The reporting entity is identified as an investment adviser and a non-U.S. institution, and is a subsidiary of Sumitomo Mitsui Trust Group Inc. and Nikko Asset Management Co., Ltd., which are classified as parent holding companies or investment advisers.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of 10x Genomics, Inc.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory filing disclosing a passive ownership stake, with no inherent positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a routine regulatory disclosure required by the U.S. Securities and Exchange Commission (SEC) when an entity acquires beneficial ownership of more than 5% of a company's voting stock. It signifies a significant, but passive, investment by an institutional asset manager in 10x Genomics, Inc., a company operating in the life sciences and biotechnology sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holders, potentially indicating institutional confidence in the company.
• Company Management: Informs management of a significant, passive shareholder.

Key Dates

Keywords

10x Genomics, Nikko Asset Management Americas, Beneficial Ownership, Schedule 13G, Class A Common Stock, Institutional Investment, Sumitomo Mitsui Trust Group